Skip to content
type1.science
Phase 2Not yet recruitingNCT07216391

TrialNet platform: teplizumab vs low-dose ATG to delay stage-3 T1D

NIDDK TrialNet adaptive platform trial comparing teplizumab with low-dose anti-thymocyte globulin in stage-2 T1D to test whether ATG can match or beat the approved delay therapy.

Primary endpoints

  • Change in DPTRS at six months

Results so far

No results posted yet.